Following Announcement of Trial Results, Decision Resources Has Reduced its Sales Forecast for Avastin by Nearly $1 Billion in 2017

Marcus Hoyle, analyst at Decision Resources is available to discuss the recently announced NSABP C-08 clinical trial results in which Roche/Chugai's monoclonal antibody Avastin* (bevacizumab) failed to meet its primary endpoint of reducing the recurrence of early-stage (adjuvant) colon cancer. As a result of this recently publicized news, Decision Resources has reduced its sales forecast for Avastin in 2017 by nearly $1 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

  Mr. Hoyle is available to discuss:    --  The impact of this Phase III clinical trial result on sales of Avastin       through 2017 in the world's major pharmaceutical markets   --  Whether the results of the NSABP C-08 clinical trial may cast doubt       over a second colon cancer clinical trial for Avastin, the AVANT       trial, which is currently underway    --  How the results of the NSABP C-08 clinical trial might affect the       development of other monoclonal antibodies for early stage colon       cancer treatment  

To speak with Mr. Hoyle, please contact Christopher Comfort at 781-296-2597 or

*Avastin is marketed by Genentech, Inc. which was purchased by F. Hoffman-La Roche Ltd. in March, 2009.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Christopher Comfort   781-296-2597    /PRNewswire -- April 23/ 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages Over Sales-Leading ReoPro

View Now